focus -WSS

focus

author：explore 2025-10-02 22:40:39 - browse：14

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Alkermes shareholders re
Next article： DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

knowledge

WSS

Biden declares emergency in flood

Trump lawyer welcomes Pence testifying in Jan. 6 trial, won't say if Trump will too

Teachers share how revamped forgiveness program helped with their student loans

Illinois to ban advertising for guns allegedly marketed to kids and militants

Accuser who called Kevin Spacey 'vile sexual predator' admits he joked about incident

Eisai exec who led development of Alzheimer’s drug to retire

focus

focus

knowledge

State Dept. review finds Biden bears some blame for Afghanistan failures

Judge agrees to delay next hearing in Trump classified documents case

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The U.S. needs a new definition of substance use “recovery”

Drug repurposing or repositioning? The language matters

Elon Musk says he may need surgery before proposed 'cage match' with Mark Zuckerberg

Jerome Adams on the need for new antivirals for Covid

Tesla CFO Zachary Kirkhorn steps down, but will remain with company through year's end

State Dept. review finds Biden bears some blame for Afghanistan failures

Bursting ice dam in Alaska highlights risks of glacial flooding around the globe

focus

ACA's risk program benefits Blue Cross Blue Shield insurers

Biden targets hefty hospital 'facility fees' that often surprise patients

Biden targets hefty hospital 'facility fees' that often surprise patients

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Biden targets hefty hospital 'facility fees' that often surprise patients

Prince Harry and Meghan to work on film adaptation of 'Meet Me at the Lake' novel

hotspot

focus

knowledge

focus